IRB #

STUDY00015816

Title

A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma (KEYNOTE-224)

Principal Investigator

Adel Kardosh

Study Purpose

The purpose of this study is to evaluate the safety and tolerability of the study drug, Pembrolizumab, in patients with advanced hepatocellular carcinoma (HCC).

Medical Condition(s)

Advanced Liver Cancer (Hepatocellular Carcinoma)
Advanced HCC

Eligibility Criteria

≥ 18 years of age
Liver Cancer (BCLC) Stage C or B
Previously untreated

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

You will receive the study drug (Pembrolizumab) until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment.
After you finish treatment your doctor will continue to watch you for side effects and follow your condition until study completion.

Minors Included

No

Contact

OHSU Knight Cancer Institute Information line 503-494-1080

Sponsor

Merck Sharp & Dohme Corp., (a subsidiary of Merck & Co. Inc.)

Recruitment End

01/01/2020

Compensation Provided

No


Go Back